Search Results - "Assaf Pastrana, J.D."

2193P Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology by Perez, S.M. Cedres, Valdivia, A.A., Pastrana, J.D. Assaf, Gomez, P. Iranzo, Perez, A. Callejo, Aranda, N. Pardo, Mendivil, A.F. Navarro, Martinez-Marti, A., Priano, I., Hermida, J.M. Ucha, Garcia-Galea, E., Gonzalo, J., Caro, R., Carbonell, C., Amat, R., Dienstmann, R., Felip, E.

Get full text

937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment by Jové, M., Braña, I., Oliva Bernal, M., Hernando Calvo, A., Erasun Lecuona, C., Assaf Pastrana, J.D., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Moreno, R., Le, C., Nuciforo, P.G., Alemany, R., Capella, G., Blasco, C., Cascallo Piqueras, M., Mesia Nin, R.

Get full text

702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs) by Rezqallah Aron, M.A., Hernando-Calvo, A., Galvao de Aguiar, V., Saavedra Santa Gadea, O., Assaf Pastrana, J.D., Lostes Bardaji, M.J., Rojas Laimito, K.I., Aguilar Izquierdo, S., Berché, R., Tian, T., Bescós, C., Lorente, J., Giralt, J., Temprana-Salvador, J., Alberola, M., Dienstmann, R., Felip, E., Garralda, E., Vieito Villar, M., Brana, I.

Get full text

686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) by Mirallas, O., Marmolejo Castaneda, D.H., Illescas, D.G., Gómez-Puerto, D., Berché, R., Calvo, A.H., Vieito Villar, M., Lorini, L., Navarro, V., Assaf Pastrana, J.D., Saavedra, O., Alonso, G., Aguilar Izquierdo, S., Bescós, C., Lorente, J., Giralt, J., Dienstmann, R., Garralda, E., Felip, E., Brana, I.

Get full text

1231P Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) by Jove, M., Brana, I., Oliva Bernal, M., Hernando-Calvo, A., Erasun Lecuona, C., Assaf Pastrana, J.D., Bazan Peregrino, M., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Martinez de Villareal, J., Real, F.X., Nuciforo, P.G., Alemany, R., Capella, G., Blasi, E., Blasco, C., Cascallo Piqueras, M., Mesia Nin, R.

Get full text

166P Impact of immunotherapy (IT) on overall survival (OS) of patients with malignant pleural mesothelioma (MPM) adjusted for tumor histology by Perez, S.M. Cedres, Valdivia, A.A., Pastrana, J.D. Assaf, Gomez, P. Iranzo, Aranda, N. Pardo, Mendivil, A.F. Navarro, Martinez-Marti, A., Prina, M. Meazza, Garcia-Galea, E., Gonzalo, J., Dienstmann, R., Felip, E.

Get full text